

BETH C. DRAIN, CA CSR NO. 7152

BEFORE THE
INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE
TO THE
CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE
ORGANIZED PURSUANT TO THE
CALIFORNIA STEM CELL RESEARCH AND CURES ACT
EMERGENCY MEETING

LOCATION: VIA ZOOM

DATE: MAY 22, 2020
11 A.M.

REPORTER: BETH C. DRAIN, CA CSR
CSR. NO. 7152

FILE NO.: 2020-10

I N D E X

ITEM DESCRIPTION	PAGE NO.
OPEN SESSION:	
CALL TO ORDER.	3
ROLL CALL.	3
ACTION ITEMS:	
CONSIDERATION OF EXISTENCE OF EMERGENCY SITUATION. "EMERGENCY SITUATION" MEANS ANY OF THE FOLLOWING, AS DETERMINED BY A MAJORITY OF THE MEMBERS OF THE INDEPENDENT CITIZENS OVERSIGHT COMMITTEE: (A) WORK STOPPAGE OR OTHER ACTIVITY THAT SEVERELY IMPAIRS PUBLIC HEALTH OR SAFETY, OR BOTH. (B) CRIPPLING DISASTER THAT SEVERELY IMPAIRS PUBLIC HEALTH OR SAFETY, OR BOTH.	5
CONSIDERATION OF MODIFICATIONS TO COVID-19 PROJECTS PROGRAM ANNOUNCEMENT TO EXPAND ELIGIBILITY TO INCLUDE DISC 1 AND VACCINE DEVELOPMENT PROPOSALS AND MAKE OTHER CHANGES, INCLUDING BUT NOT LIMITED TO ALLOWING FOR SUPPLEMENTAL FUNDING FOR EXISTING CLIN2 COVID-19 AWARDS TO EXPAND ACTIVITIES TO ADDRESS COVID-19.	8, 44
APPOINTMENT AND REAPPOINTMENT OF SCIENTIFIC MEMBERS TO THE GRANTS WORKING GROUP.	47
DISCUSSION ITEMS:	
PUBLIC COMMENT.	NONE
ADJOURNMENT.	50

BETH C. DRAIN, CA CSR NO. 7152

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

MAY 22, 2020; 11 A.M.

CHAIRMAN THOMAS: THANK YOU, MARIA. I'D LIKE TO CALL TODAY'S MEETING OF THE ICOC TO ORDER. THIS IS THE LATEST IN THE SERIES OF A NUMBER OF EMERGENCY MEETINGS THAT WE HAVE HAD ON THIS COVID FUNDING ROUND AND, AS ALWAYS, WANT TO THANK THE BOARD FOR MAKING ITSELF AVAILABLE IN VERY SHORT ORDER AND MARIA FOR MAKING THIS ALL HAPPEN, WHICH IS NOT AN EASY TASK.

SO WITH THAT, MARIA, WILL YOU PLEASE CALL THE ROLL.

MS. BONNEVILLE: GEORGE BLUMENTHAL.

DR. BLUMENTHAL: HERE.

MS. BONNEVILLE: LINDA BOXER. KEN BURTIS.

DR. BURTIS: PRESENT.

MS. BONNEVILLE: DEBORAH DEAS. ANNE-MARIE DULIEGE.

DR. DULIEGE: PRESENT.

MS. BONNEVILLE: YSABEL DURON.

MS. DURON: HERE.

MS. BONNEVILLE: JUDY GASSON. DAVID HIGGINS.

DR. HIGGINS: HERE. CAN I JUST ADD THANKS TO TRICIA AND DOUG AND GIL FOR MAKING THIS HAPPEN AS

BETH C. DRAIN, CA CSR NO. 7152

1 WELL .
2 MS. BONNEVILLE: STEPHEN JUELSGAARD .
3 MR. JUELSGAARD: HERE .
4 MS. BONNEVILLE: LINDA MALKAS .
5 DR. MALKAS: HERE .
6 MS. BONNEVILLE: DAVE MARTIN. I SEE YOU
7 WAVING. SHLOMO MELMED .
8 DR. MELMED: HERE .
9 MS. BONNEVILLE: LAUREN MILLER .
10 MS. MILLER: HERE .
11 MS. BONNEVILLE: ADRIANA PADILLA. JOE
12 PANETTA .
13 MR. PANETTA: HERE .
14 MS. BONNEVILLE: FRANCISCO PRIETO .
15 DR. PRIETO: HERE .
16 MS. BONNEVILLE: ROBERT QUINT .
17 DR. QUINT: HERE .
18 MS. BONNEVILLE: AL ROWLETT .
19 MR. ROWLETT: HERE .
20 MS. BONNEVILLE: SUZANNE SANDMEYER. JEFF
21 SHEEHY .
22 MR. SHEEHY: HERE .
23 MS. BONNEVILLE: OSWALD STEWARD .
24 DR. STEWARD: HERE .
25 MS. BONNEVILLE: JONATHAN THOMAS .

BETH C. DRAIN, CA CSR NO. 7152

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

CHAIRMAN THOMAS: HERE.

MS. BONNEVILLE: ART TORRES.

MR. TORRES: HERE.

MS. BONNEVILLE: KRISTINA VUORI.

DR. VUORI: HERE.

MS. BONNEVILLE: DIANE WINOKUR. YOU'RE ON MUTE, DIANE, BUT I SEE YOU SO I'M GOING TO MARK YOU DOWN AS PRESENT.

MS. BONNEVILLE: KEITH YAMAMOTO.

DR. YAMAMOTO: HERE.

MS. BONNEVILLE: OKAY. THANK YOU.

CHAIRMAN THOMAS: THANK YOU, MARIA. PROCEED TO THE ACTION ITEMS ON TODAY'S AGENDA. NO. 3 ON IT IS CONSIDERATION OF EXISTENCE OF EMERGENCY SITUATION. EMERGENCY SITUATION MEANS ANY OF THE FOLLOWING AS DETERMINED BY A MAJORITY OF THE MEMBERS OF THE ICOC: A, WORK STOPPAGE OR OTHER ACTIVITY THAT SEVERELY IMPAIRS PUBLIC HEALTH OR SAFETY OR BOTH; B, CRIPPLING DISASTER THAT SEVERELY IMPAIRS PUBLIC HEALTH OR SAFETY OR BOTH.

AS YOU KNOW FROM PAST EMERGENCY SESSIONS, WE ARE REQUIRED TO VOTE ON THIS ITEM AT THE OUTSET EACH TIME. SO, MARIA, WILL YOU PLEASE CALL THE ROLL.

MS. BONNEVILLE: DO WE NEED A MOTION,

BETH C. DRAIN, CA CSR NO. 7152

1 JAMES?
2 MR. HARRISON: WE NEED A MOTION.
3 DR. BLUMENTHAL: I SO MOVE.
4 DR. YAMAMOTO: SECOND.
5 MS. BONNEVILLE: WHO WAS THE SECOND?
6 DR. YAMAMOTO: KEITH.
7 CHAIRMAN THOMAS: THANK YOU, MARIA.
8 MS. BONNEVILLE: GEORGE BLUMENTHAL.
9 DR. BLUMENTHAL: YES.
10 MS. BONNEVILLE: LINDA BOXER. KEN BURTIS.
11 DR. BURTIS: YES.
12 MS. BONNEVILLE: DEBORAH DEAS. ANNE-MARIE
13 DULIEGE.
14 DR. DULIEGE: YES.
15 MS. BONNEVILLE: YSABEL DURON.
16 MS. DURON: YES.
17 MS. BONNEVILLE: JUDY GASSON. DAVID
18 HIGGINS.
19 DR. HIGGINS: YES.
20 MS. BONNEVILLE: STEPHEN JUELSGAARD.
21 MR. JUELSGAARD: YES.
22 MS. BONNEVILLE: LINDA MALKAS.
23 DR. MALKAS: YES.
24 MS. BONNEVILLE: DAVE MARTIN. I NEED TO
25 FIND DAVE, AND ARE YOU GIVING ME A THUMBS UP? YES.

BETH C. DRAIN, CA CSR NO. 7152

1 THANK YOU, DAVE.
2 SHLOMO MELMED.
3 DR. MELMED: YES.
4 MS. BONNEVILLE: LAUREN MILLER.
5 MS. MILLER: YES.
6 MS. BONNEVILLE: ADRIANA PADILLA. JOE
7 PANETTA.
8 MR. PANETTA: YES.
9 MS. BONNEVILLE: FRANCISCO PRIETO.
10 DR. PRIETO: AYE.
11 MS. BONNEVILLE: ROBERT QUINT.
12 DR. QUINT: YES.
13 MS. BONNEVILLE: AL ROWLETT.
14 MR. ROWLETT: YES.
15 MS. BONNEVILLE: SUZANNE SANDMEYER. JEFF
16 SHEEHY.
17 MR. SHEEHY: YES.
18 MS. BONNEVILLE: OSWALD STEWARD.
19 DR. STEWARD: YES.
20 MS. BONNEVILLE: JONATHAN THOMAS.
21 CHAIRMAN THOMAS: YES.
22 MS. BONNEVILLE: ART TORRES.
23 MR. TORRES: AYE.
24 MS. BONNEVILLE: KRISTINA VUORI.
25 DR. VUORI: YES.

BETH C. DRAIN, CA CSR NO. 7152

1 MS. BONNEVILLE: DIANE WINOKUR.

2 MS. WINOKUR: YES.

3 MS. BONNEVILLE: KEITH YAMAMOTO.

4 DR. YAMAMOTO: YES.

5 MS. BONNEVILLE: DOUG ZIEDONIS.

6 THANK YOU. MOTION CARRIES.

7 CHAIRMAN THOMAS: ON TO ITEM NO. 4,

8 CONSIDERATION OF MODIFICATION TO COVID-19 PROJECTS

9 PROGRAM ANNOUNCEMENT TO EXPAND ELIGIBILITY TO

10 INCLUDE DISC1 AND VACCINE DEVELOPMENT PROPOSALS AND

11 MAKE OTHER CHANGES INCLUDING, BUT NOT LIMITED TO,

12 ALLOWING FOR SUPPLEMENTAL FUNDING FOR EXISTING CLIN2

13 COVID-19 AWARDS TO EXPAND ACTIVITIES TO ADDRESS

14 COVID-19.

15 WE'RE GOING TO BE TAKING UP THESE IN A

16 COUPLE OF PARTS. THE FIRST PART IS GOING TO BE

17 DEALING WITH THE DISC1 AND VACCINE TOPICS. WE'LL

18 HAVE A PRESENTATION FROM DR. SAMBRANO, AT WHICH

19 POINT WE WILL ENTERTAIN A MOTION TO APPROVE THAT,

20 AND THEN WE'LL MOVE ON TO THE SUPPLEMENTAL AWARDS

21 TOPIC SEPARATELY.

22 I WANT TO AT THE OUTSET GIVE A SHOUT OUT

23 TO MR. SHEEHY WHOSE SUGGESTION TO DISCUSS THE IDEA

24 OF EXPANDING THE PROGRAM ANNOUNCEMENT TO INCLUDE

25 VACCINE DEVELOPMENT LED TO A ROBUST DISCUSSION

BETH C. DRAIN, CA CSR NO. 7152

1 AMONGST THE TEAM THIS WEEK AND TO THE TOPIC THAT'S
2 GOING TO BE DISCUSSED TODAY. SO THANK YOU VERY
3 MUCH, JEFF, FOR THAT.

4 WANT TO TURN IT OVER AT THIS POINT TO DR.
5 SAMBRANO FOR THE PRESENTATION. THE CONCEPT PLAN AS
6 REVISED IS ON OUR WEBSITE WHICH YOU'VE ALL HAD A
7 CHANCE TO LOOK AT. SO, DR. SAMBRANO.

8 DR. SAMBRANO: THANK YOU, MR. CHAIRMAN.
9 GOOD MORNING, EVERYONE.

10 SO JUST AS SOME BACKGROUND. DOUG, IF YOU
11 COULD GO TO THE NEXT SLIDE. AS WE ALL KNOW, THIS
12 COVID-19 PROGRAM WAS LAUNCHED JUST ABOUT TWO MONTHS
13 AGO, SO THIS WAS IN LATE MARCH THAT THIS WAS ISSUED.
14 AND WE TOOK AND OPENED UP SOME OF OUR PARTNERING
15 OPPORTUNITIES IN ORDER TO FACILITATE IT. AND THIS
16 INCLUDED THE BOARD APPROVING AN ALLOCATION OF FIVE
17 MILLION IN ORDER TO SUPPORT THE PROGRAM.

18 THE NEXT SLIDE. AS WITH ANY PROGRAM THAT
19 WE LAUNCH, PARTICULARLY ONE LIKE THIS ONE WHERE
20 WE'RE TRYING TO MOVE VERY QUICKLY, WE OFTEN WILL
21 IDENTIFY ELEMENTS THAT COULD IMPROVE THE PROCESS OR
22 MAKE THE PROGRAM JUST MORE IMPACTFUL IN GENERAL.

23 SO AS SUCH, I'M GOING TO GO OVER SOME
24 AMENDMENTS THAT WE ARE PROPOSING FOR THIS CONCEPT
25 THAT WE THINK ARE GOING TO BE AN IMPROVEMENT ON IT.

BETH C. DRAIN, CA CSR NO. 7152

1 SO JUST VERY BRIEFLY, ONE IS TO INCREASE THE SCOPE
2 OF EARLY STAGE OPPORTUNITIES IN THE DISCOVERY AND
3 TRANSLATIONAL STAGE TO INCLUDE VACCINE DEVELOPMENT
4 AS A POTENTIAL VITAL RESEARCH OPPORTUNITY.
5 SECONDLY, TO INCLUDE AN OPPORTUNITY FOR STUDIES ON
6 NOVEL IDEAS AND BIOLOGICAL MECHANISMS BY OPENING THE
7 DISC1 PROGRAM ANNOUNCEMENT. THIRD, TO INCLUDE A
8 REQUIREMENT FOR OUTREACH TO UNDERSERVED POPULATIONS
9 IN ALL CLINICAL TRIAL PROPOSALS. THIS IS SOMETHING
10 THAT WE DID FOR THE CONVALESCENT PLASMA PROGRAM,
11 BUT --

12 MR. TORRES: HAS TO BE KNOWN AS THE DURON
13 AMENDMENT.

14 DR. SAMBRANO: I'M SORRY?

15 MR. TORRES: THAT SHOULD BE KNOWN AS THE
16 DURON AMENDMENT.

17 DR. SAMBRANO: YES.

18 DR. DURON: THANK YOU, ART.

19 DR. SAMBRANO: FOURTH, WE WANT TO INCREASE
20 THE AWARD LIMIT ON THE DISC2 PROJECTS AND ADJUST
21 SOME OF THE LANGUAGE ON THE SIX-MONTH DELIVERABLES.
22 AND THEN LASTLY, TO ALLOW SUPPLEMENTAL FUNDING FOR
23 ACTIVE COVID-19 CLINICAL TRIALS TO EXPAND THEIR
24 EFFORTS.

25 SO LET ME START WITH THE NEXT SLIDE

BETH C. DRAIN, CA CSR NO. 7152

1 PLEASE. SO THE FIRST IS RELATED TO VACCINE
2 DEVELOPMENT. SO WHAT WE WANT TO DO IS EXPAND THE
3 ELIGIBILITY OF PROJECTS AT THE DISCOVERY AND
4 TRANSLATIONAL STAGE TO INCLUDE THOSE THAT DON'T
5 NECESSARILY INVOLVE STEM OR PROGENITOR CELLS. THERE
6 ARE SOME VACCINE PROJECTS THAT DO. AND SO SOME OF
7 THOSE HAVE COME IN, BUT THERE ARE MANY THAT DON'T.
8 AND SO JUST TO AVOID CERTAINLY SOME OF THE ISSUES
9 THAT WE HAVE HAD IN TERMS OF DETERMINING
10 ELIGIBILITY, BUT ALSO JUST TO EXPAND IT TO INCLUDE
11 MORE INTERESTING AND NOVEL OPPORTUNITIES, WE WANTED
12 TO ALLOW VACCINE PROJECTS TO COME IN.

13 AS WE DID WITH CONVALESCENT PLASMA, WE DO
14 HAVE THE OPPORTUNITY TO ALLOW THESE TO BE FUNDED IF
15 THEY'RE DEEMED A VITAL RESEARCH OPPORTUNITY. SO
16 THIS IS DONE BOTH BY THE GRANTS WORKING GROUP AS
17 WELL AS BY THE BOARD, AND HERE JUST BY OPENING UP
18 AND ALLOWING SUCH APPLICATIONS TO COME IN.

19 NOW, IF THE BOARD DETERMINES THAT VACCINE
20 DEVELOPMENT PROJECTS ARE A POTENTIAL VITAL RESEARCH
21 OPPORTUNITY, THEN WHAT WE WOULD DO IS AMEND THE
22 PROGRAM ANNOUNCEMENT TO INCLUDE THOSE PROJECTS AS
23 ELIGIBLE FOR FUNDING, AND THEN THOSE WOULD UNDERGO A
24 GWG REVIEW USING THE SAME PROCESS THAT WE HAVE DONE
25 FOR THE CONVALESCENT PLASMA PROGRAMS THAT REQUIRE

BETH C. DRAIN, CA CSR NO. 7152

1 THAT VITAL RESEARCH OPPORTUNITY VOTE.

2 NEXT SLIDE PLEASE. SO JUST I WANT TO SAY
3 A COUPLE OF WORDS AS TO WHY VACCINE DEVELOPMENT MAY
4 OFFER A POTENTIAL VITAL RESEARCH OPPORTUNITY. WE
5 KNOW THAT CONTROLLING THIS VIRUS IS GOING TO BE
6 IMPORTANT, AND THE CONTROL OF IT WILL ULTIMATELY
7 REQUIRE DEVELOPMENT OF IMMUNITY VIA A BROAD
8 PERCENTAGE OF THE POPULATION. ACHIEVING THAT OFTEN
9 IS THROUGH EFFECTIVE VACCINES. OF COURSE, THE
10 DEVELOPMENT OF SUCH VACCINE USUALLY REQUIRES YEARS
11 TO PRODUCE SUCCESSFULLY.

12 SO WE FELT THAT SUPPORTING MULTIPLE
13 EFFORTS AND TRYING NOVEL APPROACHES TO VACCINE
14 DEVELOPMENT AND GETTING SOME OF THOSE IDEAS GOING
15 MAY INCREASE THE LIKELIHOOD THAT WE IDENTIFY A
16 SUCCESSFUL VACCINE IN A SHORTER TIME SPAN.

17 IN ADDITION, IN CALIFORNIA WE HAVE A LOT
18 OF GOOD GROUPS THAT HAVE THE INNOVATIVE POTENTIAL TO
19 COME UP WITH SOMETHING THAT IS NEW. AND SO WE DO
20 WANT TO LEVERAGE THE CALIFORNIA SCIENTIFIC
21 ESTABLISHMENT TOWARD THOSE EFFORTS IF WE CAN.

22 THE NEXT SLIDE PLEASE. SO THAT'S THE
23 VACCINE DEVELOPMENT. THE SECOND ITEM IS TO OPEN THE
24 DISCOVERY 1 PROGRAM ANNOUNCEMENT. AND SO THE DISC1
25 IS AN OPPORTUNITY THAT OFFERS FUNDING FOR NEW IDEAS

BETH C. DRAIN, CA CSR NO. 7152

1 AND FOR STUDYING BIOLOGICAL MECHANISMS. THIS IS THE
2 EARLIEST IN OUR PIPELINE OF PROJECTS THAT WE FUND.
3 THE AWARD LIMIT FOR THIS WOULD BE 150,000 WITH A
4 MAXIMUM AWARD DURATION OF 12 MONTHS AND THE
5 SIX-MONTH DELIVERABLE WHICH WOULD BE TO EITHER
6 CONFIRM OR REJECT THE HYPOTHESIS THAT THEY PROPOSE.

7 SO THAT'S THE SECOND. NEXT SLIDE PLEASE.
8 THIRDLY, OUTREACH TO UNDERSERVED POPULATIONS. SO AS
9 I MENTIONED EARLIER, THIS IS SOMETHING THAT WE DID
10 FOR THE CONVALESCENT PLASMA PROGRAM, BUT WE WANT TO
11 EXPAND IT BROADLY ACROSS ALL CLINICAL TRIAL
12 PROPOSALS. AND SO WHAT THIS WOULD DO IS MAKE IT A
13 REQUIREMENT THAT ALL APPLICANTS WILL HAVE A WRITTEN
14 PLAN IN THEIR APPLICATION FOR HOW THEY WILL CONDUCT
15 OUTREACH AND INCLUDE STUDY PARTICIPANTS BY OR FROM
16 UNDERSERVED AND DISPROPORTIONATELY AFFECTED
17 POPULATIONS. AND WE WILL ALSO STRESS THAT SUCH
18 PROJECTS THAT HAVE HIGH QUALITY PLANS WOULD GET
19 PRIORITY.

20 NEXT SLIDE PLEASE. OKAY. AND THEN WE
21 ALSO WANTED TO MAKE SOME ADJUSTMENTS TO THE DISC2
22 AND TRAN1 REQUIREMENTS THAT ARE ALREADY WITHIN THE
23 CONCEPT. SO THE FIRST IS TO INCREASE THE DISC2
24 AWARD LIMIT TO 250,000. IT WAS PREVIOUSLY 150. WE
25 WANTED TO MAKE THIS ADJUSTMENT, IN PART, TO IMPROVE

BETH C. DRAIN, CA CSR NO. 7152

1 THE LIKELIHOOD THAT THOSE THAT COME IN TO DEVELOP A
2 CANDIDATE ARE ABLE TO PROPOSE A FEASIBLE PROJECT.
3 WE HAVE BEEN GETTING A GOOD NUMBER OF PROPOSALS, BUT
4 I THINK INCREASING THE AMOUNT WOULD ALLOW THEM TO
5 PROPOSE SOMETHING THAT IS MORE LIKELY TO BE
6 FEASIBLE. IT ALSO ALLOWS FOR PROJECTS SUCH AS THE
7 VACCINE DEVELOPMENT TO TAKE ADVANTAGE OF THE LARGER
8 AMOUNT IN ORDER TO BE SUCCESSFUL.

9 WE ALSO ARE ADDING SOME CLARIFYING
10 LANGUAGE JUST TO MAKE IT CLEAR THAT TOOL AND
11 TECHNOLOGY DEVELOPMENT IS ALSO ONE OF THE GOALS OF
12 DISC2. SO IN ADDITION TO DEVELOPING THERAPEUTIC
13 CANDIDATES, IT HAS BEEN UNCLEAR TO SOME APPLICANTS
14 WHETHER OR NOT TOOLS AND TECHNOLOGIES CAN ALSO BE
15 DEVELOPED. AND THEY CAN, SO WE'RE JUST CLARIFYING
16 THE LANGUAGE ON THAT.

17 AND THEN, LASTLY, WE WANT TO ADJUST THE
18 SIX-MONTH DELIVERABLE FOR THE TRAN1 PROJECTS TO
19 COMPLETE THEIR STUDIES BY THE SIX-MONTH MARK, BUT
20 ALLOW THEIR PRE-IND MEETING TO OCCUR AFTERWARDS.
21 ***PREVIOUSLY WE HAD AS THE SIX MONTH DELIVERABLE
22 THAT THEY CONDUCT THEIR PRE-IND MEETING, BUT OFTEN
23 WHAT HAPPENS IS WE WANT THEM TO BE READY TO GO AS
24 THEY COME IN. SO WE WANT THEM TO TAKE FULL
25 ADVANTAGE OF THE SIX MONTHS TO COMPLETE THE STUDIES

BETH C. DRAIN, CA CSR NO. 7152

1 THEY NEED BECAUSE OFTEN SCHEDULING THE PRE-IND
2 MEETING MAY TAKE A COUPLE OF MONTHS. SO WE WANTED
3 TO MAKE THAT ADJUSTMENT.

4 AND, MR. CHAIRMAN, I WILL MAYBE PAUSE HERE
5 BEFORE I GO INTO THE SUPPLEMENTAL FUNDING IF THERE
6 ARE ANY QUESTIONS AND IF YOU WANT TO TAKE THESE
7 ITEMS TOGETHER.

8 CHAIRMAN THOMAS: DO WE HAVE A MOTION TO
9 ADOPT THE ITEMS JUST REVIEWED BY DR. SAMBRANO?

10 DR. HIGGINS: SO MOVED.

11 DR. VUORI: SECOND.

12 CHAIRMAN THOMAS: THANK YOU.

13 MR. TORRES: IS THAT A MOTION FOR BOTH
14 CATEGORIES TO BE FUNDED TOGETHER OR SEPARATELY?

15 CHAIRMAN THOMAS: THIS IS A MOTION FOR THE
16 ITEMS THAT GIL JUST REVIEWED BEFORE WE GET TO THE
17 CONCEPT OF THE SUPPLEMENTAL AWARDS. SO THERE WERE
18 SEVERAL HERE. MOTION IS TO SORT OF LUMP THEM
19 TOGETHER AND TAKE A VOTE ON ALL OF THEM AT ONCE.

20 MR. TORRES: OKAY. I WAS JUST CONCERNED
21 ABOUT CONFLICTS. THANK YOU.

22 CHAIRMAN THOMAS: SO MOVED BY DR. HIGGINS,
23 SECONDED BY DR. VUORI. IS THERE DISCUSSION ON THIS
24 MOTION BY MEMBERS OF THE BOARD?

25 DR. DULIEGE: J.T., I HAVE A QUESTION.

BETH C. DRAIN, CA CSR NO. 7152

1 CHAIRMAN THOMAS: YES, DR. DULIEGE.

2 DR. DULIEGE: SO I UNDERSTAND THE
3 ADJUSTMENT TO THE TOTAL AMOUNT AND THE TIMING OF THE
4 DELIVERABLES, BUT I WANT TO BE CLEAR ON SOMETHING
5 I'M SLIGHTLY CONFUSED ABOUT. ON THIS FIRST SLIDE,
6 IT SAYS THAT THE PROJECT COULD BE FUNDED EVEN -- THE
7 VACCINE PROJECT EVEN IF IT IS NOT STEM CELL RELATED
8 OR DID I MISUNDERSTAND?

9 CHAIRMAN THOMAS: NO. THAT'S CORRECT.
10 THE CONCEPT HERE IS PRECISELY WHY WE ARE LOOKING AT
11 THIS AS A POTENTIAL VITAL RESEARCH OPPORTUNITY WHICH
12 CONTEMPLATES SOMETHING THAT DOES NOT HAVE A STEM
13 CELL COMPONENT IF THE BOARD SO CHOOSES TO INCLUDE IT
14 WITHIN THE SCOPE OF THE PROGRAM.

15 DR. DULIEGE: SO I'D LIKE TO THEN MAKE A
16 COMMENT ABOUT THAT. FIRST OF ALL, IN TERMS OF
17 VACCINE DEVELOPMENT, I'M NOT SURE EXACTLY WHAT KIND
18 OF VACCINE COULD BE STEM CELL RELATED TO BEGIN WITH,
19 BUT MAYBE I'M SURE MARIA MILLAN OR OTHER MEMBER OF
20 THE CIRM COULD EXPLAIN.

21 BUT I'M THEN NOT SURE WHY WE WOULD USE
22 CIRM MONEY TO FUND A VACCINE EFFORT THAT WOULD NOT
23 BE STEM CELL RELATED. IN FACT, THAT THIS IS
24 IMPORTANT AND URGENT, WE ALL KNOW THAT, BUT THERE
25 ARE MANY OTHER OPPORTUNITIES FOR FUNDING FROM THE

BETH C. DRAIN, CA CSR NO. 7152

1 NIH, FROM THE GATES FOUNDATION, AND FROM COMPANIES
2 AS WELL. WHY WOULD WE PUT CIRM STEM CELL-RELATED
3 MONEY INTO THAT POT WHEN WE ARE SO LIMITED IN TERMS
4 OF MONEY LEFT TO FUND STEM-CELL RELATED PROJECTS IN
5 GENERAL? MAYBE I'M MISSING THE POINT. I'M JUST
6 ASKING CLARIFICATION.

7 CHAIRMAN THOMAS: I'LL START ON THAT AND
8 PERHAPS DR. SAMBRANO OR ANYONE ELSE WHO WOULD LIKE
9 TO FOLLOW. SO THIS IS THE THIRD TOPIC THAT WE HAVE
10 TAKEN UP UNDER THE GENERAL AREA OF VITAL RESEARCH
11 OPPORTUNITIES, THE FIRST HAVING BEEN GENE THERAPIES,
12 THE SECOND CONVALESCENT PLASMA, THIS BEING THE
13 THIRD. SO THE IDEA IS THAT WE FEEL LIKE WE WANT TO
14 BE ABLE TO FUND PROJECTS AS PART OF THIS
15 EXTRAORDINARY WORLDWIDE EFFORT THAT'S GOING ON HERE.
16 AND TO THE EXTENT THERE ARE VACCINE OPTIONS THAT
17 DON'T INCLUDE STEM-CELL ELEMENTS, BUT THAT COULD BE
18 FUNDED IN THE RANGES THAT DR. SAMBRANO HAS LAID OUT,
19 IT WAS OUR FEELING AS THE TEAM THAT THIS IS
20 SOMETHING THAT WE SHOULD BE LOOKING AT.

21 THERE ARE ACTUALLY SOME VACCINE PROJECTS
22 THAT DO HAVE STEM-CELL ELEMENTS. DR. SAMBRANO
23 REFERRED TO THOSE IN HIS PRESENTATION. BUT THAT'S
24 THE GENERAL IDEA. WE'RE GOING A LITTLE BIT ABOVE
25 AND BEYOND HERE TO TRY TO HELP IMPACT THIS EFFORT

BETH C. DRAIN, CA CSR NO. 7152

1 THAT WE ARE NOW A PART OF. GIL, DO YOU WANT TO ADD
2 TO THAT?

3 DR. SAMBRANO: CERTAINLY I CAN SPEAK A
4 LITTLE BIT TO PROJECTS THAT DO INVOLVE STEM CELLS
5 THAT ARE FOCUSED ON VACCINE DEVELOPMENT. SOME OF
6 THOSE ARE PLATFORMS THAT ARE USED THAT ARE STEM CELL
7 BASED THAT MAY HELP IDENTIFY VACCINE CANDIDATES. WE
8 HAVE GOTTEN OTHERS THAT FOCUS ON PROGENITOR CELLS.
9 SO THEY FOCUS ON STIMULATING PEAK STEM CELL MEMORY
10 CELLS. AND WE'VE ACTUALLY BEEN LOOKING AT THE
11 ARGUMENT THAT SOME HAVE PRESENTED THAT TARGETING
12 NAIVE B CELLS AND STIMULATING THEM WOULD CONSTITUTE
13 OR FIT WITHIN OUR DEFINITION OF A PROGENITOR CELL.

14 SO THERE ARE CERTAINLY WAYS IN WHICH SOME
15 CAN ARGUE THAT VACCINE DEVELOPMENT CAN INVOLVE STEM
16 OR PROGENITOR CELLS. BUT JUST TO AVOID GETTING INTO
17 THOSE NUANCES OF THAT DISCUSSION, IF WE OPEN IT UP
18 AS ANY VACCINE DEVELOPMENT PROJECT, THEN THAT WOULD
19 ALLOW US TO CONSIDER ANY OF THEM.

20 DR. YAMAMOTO: SO I AGREE WITH
21 ANNE-MARIE'S CONCERNS. I THINK THAT THERE ARE TWO
22 FOCAL POINTS. ONE IS AS GIL JUST REMINDED US.
23 THERE ARE VACCINE APPROACHES THAT CAN REALLY USE
24 STEM CELLS, PROGENITOR CELLS TO ADVANTAGE. AND
25 THOSE, OF COURSE, WE SHOULD INVITE AND SUPPORT

BETH C. DRAIN, CA CSR NO. 7152

1 VIGOROUSLY IF THE QUALITY OF THE PROPOSAL IS GOOD.
2 THAT REALLY FITS THE MAIN FOCUS OF WHAT CIRM IS
3 ABOUT.

4 BUT I THINK DEPARTING FROM THAT AND SIMPLY
5 SAYING BECAUSE VACCINES ARE IMPORTANT, WE'LL JUST
6 INVITE ANYBODY WITH AN IDEA FOR VACCINE DEVELOPMENT
7 TO SUBMIT TO THIS BODY FOR SUPPORT, I'M NOT -- IN MY
8 VIEW, I WOULD QUESTION THE JUSTIFICATION FOR THAT.
9 ANNE-MARIE IS RIGHT, THAT THERE ARE MANY SOURCES.
10 THE CONGRESS IN THE THIRD EMERGENCY PACKAGE, WE'RE
11 ON THE FIFTH RIGHT NOW, BUT ON THE THIRD EMERGENCY
12 PACKAGE SPECIFIED 974 MILLION, ALMOST A BILLION
13 DOLLARS, TO SIX AGENCIES OF THE NIH SPECIFICALLY FOR
14 COVID RESEARCH. AND THAT'S JUST ONE AGENCY THAT HAS
15 DONE THAT. OTHER FEDERAL AGENCIES AND PRIVATE
16 AGENCIES AND FOUNDATIONS, AS ANNE-MARIE ALREADY
17 SAID, HAVE ALSO SET ASIDE FUNDS.

18 WE AT UCSF HAVE SET ASIDE SPECIFIC FUNDS
19 AND ACTUALLY JUST HAVE AWARDED SEVERAL MILLION
20 DOLLARS OF GRANTS FOR COVID RESEARCH, AND WE ARE
21 CERTAINLY IN NO MEANS ALONE IN THAT.

22 SO I THINK THAT THERE'S A CLEAR
23 UNDERSTANDING THAT THIS IS URGENT AND IMPORTANT AND
24 THAT IT IS BEING ADDRESSED, AND THAT CIRM WOULD BE
25 WELL ADVISED TO KIND OF STAY IN OUR LANE BECAUSE

BETH C. DRAIN, CA CSR NO. 7152

1 THERE'S IMPORTANT WORK TO BE DONE ACROSS THE BOARD
2 WITH STEM CELLS. TO THE EXTENT THAT VACCINE
3 DEVELOPMENT CAN BE PART OF THAT, THAT'S GREAT. BUT
4 I THINK WE SHOULD KIND OF BE LOYAL TO THE FOCUS.

5 MS. BONNEVILLE: J.T., MR. SHEEHY HAS HIS
6 HAND UP.

7 CHAIRMAN THOMAS: MR. SHEEHY.

8 MR. SHEEHY: THANK YOU, J.T.

9 SO I GUESS MY QUESTION ALMOST SEEMS LIKE
10 THAT THE ARGUMENT'S BEING MADE AGAINST DOING
11 ANYTHING IN COVID. IF YOU LOOK AT THE PRODUCTS THAT
12 ARE MOST EFFECTIVE AGAINST INFECTIOUS DISEASES,
13 THEY'RE VACCINES AND ANTIVIRALS. THE ONE CLINICAL
14 PROGRAM THAT WE ARE DOING IS NOT IN SCOPE, THE
15 BIGGEST CLINICAL PROGRAM, RIGHT. AND THEN WE HAVE
16 ONE THAT REALLY IS ADDRESSING SOMETHING THAT
17 HAPPENS, RIGHT, POSTINFECTION OF A COMPLICATION
18 WHICH IS WHAT -- THE OTHER ONE WE DID WAS FOR
19 MESENCHYMAL STEM CELLS, WHICH IS FOR ARDS. BUT TO
20 ME, IF WE WANT TO DO SOMETHING ABOUT COVID, WE
21 SHOULD FOCUS, AT LEAST SOMEWHAT, ON THE PRODUCTS
22 THAT ARE USEFUL AGAINST INFECTIOUS DISEASES, WHICH
23 ARE VACCINES AND ANTIVIRALS.

24 TO THE DEGREE THAT WE FORCE APPLICANTS TO
25 KIND OF FIT IN A STEM CELL -- TO TRY TO TAILOR THEIR

BETH C. DRAIN, CA CSR NO. 7152

1 PROJECTS IN ORDER TO SATISFY A STEM CELL
2 REQUIREMENT, WE ARE MAKING IT A CHALLENGE FOR US TO
3 EFFECTIVELY ADDRESS COVID.

4 I UNDERSTOOD THE DESIRE OF THIS BOARD IS
5 TO SIGNIFICANTLY TRY TO DO SOMETHING ABOUT COVID.
6 AND VACCINE DEVELOPMENT, WE HAVE HAD SOME PROJECTS
7 COME IN. THEY DIDN'T REACH THE FUNDING LEVEL, AND
8 THERE ARE A NUMBER OF REASONS WHY THAT'S SO. BUT
9 THE IDEA THAT WE MIGHT HIT UPON SOMETHING THAT'S
10 NOVEL AND SOMETHING THAT IS TRULY INNOVATIVE, IS
11 SOMETHING THAT'S EXTREMELY HIGH RISK IS SOMETHING
12 THAT TO ME SEEMS TO BE VALUABLE IF WE'RE GOING TO BE
13 IN THE COVID SPACE.

14 I DO TAKE PEOPLE'S POINT THAT MONEY IS
15 BEING POURED INTO COVID RESEARCH FROM ALL CORNERS.
16 AND SO TO ME IT SEEMS LIKE YOU'RE REALLY ASKING
17 ABOUT WHAT IS THE PURPOSE OF DOING A COVID RFA TO
18 BEGIN WITH AND THAT THERE'S ALL THIS MONEY OUT
19 THERE, RIGHT, THAT DOESN'T -- I MEAN WHY WE HAVE AN
20 ADVANTAGE, BECAUSE WE FUND STEM CELLS, WHEN, YOU
21 KNOW, STEM CELLS ARE NOT NECESSARILY THE BEST
22 PRODUCT, THE BEST TECHNOLOGY TO DEVELOP A VACCINE OR
23 THE BEST TECHNOLOGY FOR AN ANTIVIRAL. IT KIND OF
24 QUESTIONS WHY WE ARE DOING THIS IN THE FIRST PLACE.
25 AND EITHER WE GO IN AND WE TRY TO TARGET THE

BETH C. DRAIN, CA CSR NO. 7152

1 PRODUCTS THAT ARE MOST EFFECTIVE IN DEALING WITH
2 THIS INFECTIOUS DISEASE OR WE CONTINUE TO KIND OF
3 WORK AROUND THE EDGES.

4 SO I'M AGNOSTIC, BUT IT SEEMS TO ME IF WE
5 ARE GOING TO BE IN THE FIELD, VACCINES ARE A GREAT
6 PLACE TO BE, THAT THAT'S CERTAINLY GOING TO BE THE
7 SOLUTION TO THE VIRUS IN THE LONG TERM. BUT TO ME I
8 JUST -- THE STEM CELL HANDCUFFS, WHICH WE HAVE
9 GOTTEN AWAY FROM ALREADY IN THIS RFA, AND AS AN
10 AGENCY WE ARE TAKING A MUCH BROADER AND MUCH MORE
11 SOPHISTICATED VIEW OF WHAT OUR MISSION IS. IT'S
12 MORPHED. IF WE WERE BEING TRUE TO OUR ORIGINAL
13 MISSION, WE WOULD ONLY BE DOING EMBRYONIC STEM CELL
14 RESEARCH. SO IF THAT'S THE ARGUMENT, THAT'S WHAT
15 THE VOTERS ASKED US TO DO IN 2004. SO IT JUST
16 DEPENDS HOW PURE YOU WANT TO BE.

17 DR. MELMED: J.T.

18 CHAIRMAN THOMAS: YES, DR. MELMED.

19 DR. MELMED: I WOULD SUPPORT ANNE-MARIE
20 AND KEITH. I, TOO, CLEARLY ALL OF US RECOGNIZE THE
21 IMPERATIVE OF COVID RESEARCH. I HAVE TWO -- I DON'T
22 WANT TO REPEAT WHAT THEY SAID BECAUSE THEY SAID IT
23 SO ARTICULATELY, AND I AGREE WITH THOSE SENTIMENTS.
24 HOWEVER, I WANT TO ADD TWO THOUGHTS. ONE IS THAT
25 VACCINE DEVELOPMENT IS A HUGE, HUGE ENDEAVOR. AND

BETH C. DRAIN, CA CSR NO. 7152

1 TO THROW \$250,000 AT A VACCINE PROJECT WITH THE HOPE
2 OF HITTING A BULL'S-EYE IS PIE IN THE SKY, AND WE
3 SHOULD BE REALISTIC ABOUT THAT. IT MAY LOOK GOOD ON
4 OUR WEBSITE THAT WE ARE DOING VACCINE WORK, BUT THE
5 REALITY IS THAT THESE FOUR PROJECTS ARE NOT GOING TO
6 HAVE MAJOR SHORT-TERM IMPACTS BARRING SOME WONDERFUL
7 SERENDIPITY.

8 AND TO COME BACK TO THE ORIGINAL TRUST OF
9 THE VOTERS OF CALIFORNIA IN CIRM, I REALLY DO THINK
10 THAT WE ARE DEVIATING FROM OUR MISSION, AND I WOULD
11 NOT LIKE TO DILUTE OUR IMPACT WHICH IS SO VITAL.
12 AND BY GETTING CAUGHT UP IN THIS PROCESS, I BELIEVE
13 THAT WE ARE VULNERABLE TO BEING ACCUSED OF DILUTING
14 OUR MISSION.

15 CHAIRMAN THOMAS: THANK YOU, DR. MELMED.
16 I CALL ON MR. JUELSGAARD, BUT I DID WANT TO COMMENT
17 IN RESPONSE TO THESE REMARKS. I UNDERSTAND THE
18 POINTS. THEY'RE OBVIOUSLY VERY VALID PERSPECTIVE.
19 MY OPINION, HOWEVER, THE WHOLE NOTION OF VITAL
20 RESEARCH OPPORTUNITIES, WHICH IS PROVIDED FOR WITHIN
21 PROP 71, CONTEMPLATES AT THE APPROPRIATE TIME GOING
22 OUTSIDE THE SCOPE OF WHAT WAS ORIGINALLY DEFINED IN
23 THE PROPOSITION. AND WE HAVE DONE THAT, AGAIN,
24 TWICE BEFORE, I THINK, TO VERY GOOD EFFECT. AND
25 PERSONALLY I THINK THE OPPORTUNITY HERE TO DO

BETH C. DRAIN, CA CSR NO. 7152

1 SOMETHING THAT CAN IMPACT THE VACCINE EFFORTS, WHICH
2 IS CORRECTLY NOTED A HUGE EFFORT WORLDWIDE, THE FACT
3 THAT WE HAVE A CHANCE TO DO OUR PART HERE, TO ME, I
4 FIND SOMETHING THAT WE SHOULD DO. SO WITH THAT,
5 MR. JUELSGAARD.

6 MR. JUELSGAARD: FOUR QUICK POINTS. LAST
7 WEEK ALEX AZAR, THE HEAD OF THE DEPARTMENT OF HEALTH
8 RESOURCES REPORTED THAT THERE ARE OVER 100 GLOBAL
9 VACCINE PROJECTS ONGOING RIGHT NOW, OVER 100. SO
10 THERE'S A LOT OF EFFORT IN THIS AREA.

11 I AGREE WITH DR. MELMED. THIS IS A DROP
12 IN THE BUCKET FROM CIRM. IF WE WERE EVER TO AGREE
13 TO DO SOMETHING LIKE THIS, PROBABLY, UNLESS THERE'S
14 SOME FOLLOW-ON FUNDING, IT'S REALLY NOT GOING TO GO
15 ANYWHERE.

16 THERE'S SOMEBODY ON THE LINE BECAUSE I'M
17 HEARING FEEDBACK.

18 SO POINT 3 IS THAT THE WAY WE HAVE STARTED
19 DOWN THIS PATH IN COVID WAS THAT WE ACTUALLY WANTED
20 TO USE THE TOOLS OF REGENERATIVE MEDICINE TO SEE IF
21 WE COULD FIND SOMETHING THAT WOULD WORK IN THAT
22 AREA. AND OUR CONCERN WAS THAT NOBODY NECESSARILY
23 WOULD BE FUNDING THAT SORT OF THING. AND THEN WE
24 KIND OF GOT OFF ONTO THE AREA OF CONVALESCENT
25 THERAPY. AND THAT CAME ABOUT BECAUSE WE GOT

BETH C. DRAIN, CA CSR NO. 7152

1 APPROACHED BY AN INVESTIGATOR FROM THE CITY OF HOPE
2 WHO HAD A PROJECT READY TO GO FOR CONVALESCENT
3 PLASMA THERAPY. AND THAT GOT TO BE THE CENTERPOINT
4 OF EXPANDING OUR EFFORTS BEYOND REGENERATIVE
5 MEDICINE.

6 AND AT THE TIME I WAS A LITTLE UNCERTAIN
7 THAT THAT WAS THE RIGHT THING TO DO, BUT I DID VOTE
8 IN FAVOR OF IT. I WILL ADMIT THAT. I THINK AT THIS
9 POINT, AND I'M JUST LINING UP WITH DRS. DULIEGE,
10 YAMAMOTO, AND MELMED, I THINK WE'RE JUST GETTING WAY
11 OFF COURSE HERE.

12 THE FOURTH POINT IS THAT ANY FUNDS THAT WE
13 PROVIDE FOR VACCINE THERAPY ARE SELF FUNDS. THEY
14 CAN'T BE USED FOR ANYTHING ELSE. THERE COULD BE
15 SOME OTHER WONDERFUL IDEA, VERY DESERVED, COMING UP
16 WHETHER IN COVID OR SOMEWHERE ELSE AND WE WOULD BE
17 UNABLE TO FUND IT BECAUSE WE DECIDED TO PUT SOME
18 MONEY INTO A VACCINE PROJECT THAT'S GOING TO BE ONE
19 OF OVER A HUNDRED, THAT PROBABLY IS GOING TO REQUIRE
20 A LOT OF FUNDING FROM SOMEWHERE ELSE.

21 IN THAT REGARD, I MOVE TO AMEND THIS
22 PROPOSAL TO WITHDRAW THE APPROVAL OF THE VACCINE
23 COMPONENT OF IT.

24 DR. BLUMENTHAL: SECOND.

25 MS. BONNEVILLE: THANK YOU.

BETH C. DRAIN, CA CSR NO. 7152

1 CHAIRMAN THOMAS: WE HAVE FURTHER
2 DISCUSSION BY MEMBERS OF THE BOARD ON THIS
3 AMENDMENT?

4 DR. VUORI: I FULLY RECOGNIZE THE AMAZING
5 AMOUNT OF EFFORT ALREADY GOING ON IN THE VACCINE
6 DEVELOPMENT. NOW, THIS MAY BE DEVIATING TOO FAR.
7 I'M NOT PARTICULARLY IMPRESSED BY MANY OF THE
8 ONGOING VACCINE EFFORTS. I THINK THEY ARE SORT OF
9 OBVIOUS APPROACHES ONE WOULD TAKE IN TRYING TO COME
10 UP WITH NEUTRALIZING ANTIBODIES AGAINST THE SPIKE
11 PROTEIN AND THOSE ARE COMING OUT REALLY ACTUALLY BY
12 CIRM GRANTEES OR INDIVIDUALS WHO WORK IN THE STEM
13 CELL SPACE, ESPECIALLY AS IT COMES TO MEMORY
14 T-CELLS, LOOKING AT CD4, CD8 CELLS, AND RESPONSE IN
15 THOSE WHO HAVE SURVIVED COVID-19 INFECTION.

16 SOMEWHAT OF A DIFFERENT PICTURE IS
17 EMERGING AS TO WHAT TYPE OF VACCINE ACTUALLY
18 PROBABLY WOULD BE MOST EFFECTIVE. AND I'M A LITTLE
19 WORRIED THAT THERE'S A BIG DISCONNECT IN THE VACCINE
20 DEVELOPMENT AND UNDERSTANDING THE T-CELL BIOLOGY OF
21 COVID-19 INFECTION THAT WE ARE SORT OF MISSING AN
22 OPPORTUNITY THERE. INDIVIDUALS WHO HAVE EXPERTISE
23 IN THE SPACE OF CIRM-FUNDED RESEARCH, ESPECIALLY IN
24 THE STEM CELL SPACE AND THE HEMATOPOIETIC SYSTEM,
25 BUT WE COULD ACTUALLY MAKE A DISTINCT AND DIFFERENT

BETH C. DRAIN, CA CSR NO. 7152

1 CONTRIBUTION THAT COULD LEAD TO VACCINE DEVELOPMENT
2 DOWN THE ROAD.

3 SO I DON'T ACTUALLY OBJECT TO THE
4 ADJUSTMENT THAT'S PROPOSED, NOR THE ORIGINAL
5 VERSION. I UNDERSTAND THE INTENT, BUT JUST WANTED
6 TO MAKE THIS POINT, THAT THIS IS NOT ALL ABOUT JUST
7 M-RNA DELIVERY AND SCALING THINGS VERY FAST TO PHASE
8 2 TRIALS. I THINK THERE ARE LOTS OF THINGS THAT
9 SCIENTISTS IN CALIFORNIA CONTRIBUTE TO THE VACCINE
10 DEVELOPMENT, UNDERSTANDING, OF COURSE, THAT
11 HOPEFULLY, IF NOT CIRM, THEN MAYBE NIH PICKS UP THE
12 TAB. THANKS.

13 CHAIRMAN THOMAS: DR. YAMAMOTO, YOU'VE GOT
14 YOUR HAND UP AGAIN.

15 DR. YAMAMOTO: YES. SO I DON'T DIFFER
16 FROM THAT VIEW, AND I THINK IT ACTUALLY ALIGNS WITH
17 WHAT OTHERS HAVE SAID IN THAT WE KNOW AND WE HEARD
18 AGAIN FROM GIL THIS MORNING THAT THERE ARE
19 OPPORTUNITIES IN VACCINE DEVELOPMENT THAT EMPLOY
20 STEM CELL TECHNOLOGIES, STEM CELLS THEMSELVES,
21 VARIOUS PROGENITOR CELLS IN THE IMMUNE SYSTEM, BUT
22 NOT ACTUALLY ONLY IN THE IMMUNE SYSTEM. AND I THINK
23 A VIGOROUS CALL FROM CIRM FOR THOSE WHO WISH TO
24 ENGAGE IN VACCINE DEVELOPMENT EFFORTS THAT USE STEM
25 CELLS OR PROGENITOR CELLS IN THE COURSE OF THAT

BETH C. DRAIN, CA CSR NO. 7152

1 EFFORT COULD PUT THE KIND OF FOCUS THAT WE ARE
2 TALKING ABOUT THAT ALIGNS WITH THE MISSION OF CIRM
3 AND WILL ALSO GET DIFFERENT VOICES IN PLAY IN THE
4 VACCINE DEVELOPMENT SPACE BECAUSE THEY'RE COMING AT
5 IT THROUGH THIS PRISM OF STEM CELLS.

6 I THINK THAT, TO ME, ACTIVE PROMOTION OR
7 CALL FOR PROPOSALS IN THE VACCINE DEVELOPMENT SPACE
8 THAT USE STEM CELL TECHNOLOGY OR STEM CELLS
9 THEMSELVES WOULD BE SOMETHING THAT WOULD BE VERY
10 GOOD AND IMPORTANT FOR THIS GROUP TO DO THAT COULD
11 REALLY PROVIDE UNIQUE CONTRIBUTIONS TO WHAT, AS YOU
12 SAID, IS A VERY BROAD -- SEVERAL PEOPLE HAVE SAID
13 IT, A VERY BROADBASED EFFORT. OF COURSE, SOME OF
14 THE STUFF IS NOT GOOD, BUT THERE ARE NOVEL
15 APPROACHES BEING TAKEN. AND ONE OF THE WAYS THAT
16 CIRM COULD CONTRIBUTE TO THAT SPECTRUM OF APPROACHES
17 THAT'S GOING TO BE NECESSARY, AS STEVE SAID, TO GET
18 SOMETHING SUCCESSFUL WOULD BE TO SAY WE HAVE
19 EXPERTISE IN THINKING ABOUT BIOLOGICAL PROBLEMS
20 THROUGH THIS PRISM, AND THERE COULD BE REAL
21 ADVANTAGES TO BEING ABLE TO DEVELOP A VACCINE IN
22 THAT WAY. I THINK THAT KIND OF FOCUS WOULD BE
23 ENTIRELY APPROPRIATE, WOULD BE WITHIN THE MISSION
24 SPACE OF CIRM, AND I THINK WOULD BE CELEBRATED AND
25 RESPECTED IF WE WERE TO OPERATE IN THAT WAY.

BETH C. DRAIN, CA CSR NO. 7152

1 SO I THINK THAT THE AMENDMENT TO REMOVE
2 VACCINE DEVELOPMENT THAT'S NOT STEM CELL RELATED IS
3 SOMETHING THAT I WOULD SUPPORT, BUT I THINK I COULD
4 EASILY IMAGINE HAVING A MUCH MORE FOCUSED COMPONENT
5 HERE THAT WOULD SAY WE INVITE, VIGOROUSLY INVITE,
6 VACCINE DEVELOPMENT IDEAS THAT EMPLOY STEM CELLS,
7 PROGENITOR CELLS, AND SO FORTH.

8 MR. TORRES: THAT WOULD BE A CLEANER
9 AMENDMENT. IS THAT WHAT YOU'RE OFFERING?

10 DR. YAMAMOTO: YES.

11 MR. TORRES: I WOULD SECOND THAT.

12 DR. HIGGINS: SECOND.

13 CHAIRMAN THOMAS: OKAY. SO NOW WE HAVE AN
14 AMENDMENT TO AN AMENDMENT, OR WOULD YOU LIKE TO
15 OFFER THAT AS A FRIENDLY AMENDMENT TO
16 MR. JUELSGAARD'S AMENDMENT AND HAVE THAT BE
17 INCORPORATED INTO HIS AMENDMENT?

18 DR. YAMAMOTO: YEAH. I THINK THAT'S
19 ADMINISTRATIVELY SIMPLER.

20 CHAIRMAN THOMAS: MR. JUELSGAARD, ARE YOU
21 OKAY WITH THAT?

22 MR. JUELSGAARD: I'M THINKING. I'M QUITE
23 HAPPY WITH THAT FRIENDLY AMENDMENT.

24 MS. BONNEVILLE: WE HAVE SOME HANDS THAT
25 HAVE BEEN RAISED. I BELIEVE DR. BURTIS, DR. MARTIN,

BETH C. DRAIN, CA CSR NO. 7152

1 DR. DULIEGE HAVE COMMENTS.

2 DR. BURTIS: I JUST WANTED TO HEARTILY
3 ENDORSE WHAT KEITH JUST SAID. I AGREE WITH
4 EVERYTHING HE SAID. AND I THINK WHAT WE NEED TO DO
5 IS LEVERAGE CIRM'S STRENGTHS AND EXPERTISE AND NOT
6 JUST ITS REMAINING MONEY. SO I HEARTILY ENDORSE
7 THAT.

8 CHAIRMAN THOMAS: DR. DULIEGE.

9 DR. DULIEGE: MY COMMENT HAS BEEN ALREADY
10 ADDRESSED BY THE DISCUSSION THAT JUST CAME. I JUST
11 WANT TO SAY THAT I IN PRINCIPLE SUPPORT VACCINE
12 DEVELOPMENT, HAVING SPENT NEARLY HALF OF MY CAREER
13 DOING HIV DEVELOPMENT, AND I KNOW THE LENGTH, THE
14 COMPLEXITY, AND THE COST OF IT. BUT I WOULD ONLY
15 SUPPORT SUCH PROJECTS THAT HAVE A LINK TO STEM
16 CELLS, WIDELY NAMED STEM CELLS, RELATED RESEARCH AS
17 PER THE RECENT AMENDMENT.

18 CHAIRMAN THOMAS: MARIA, THERE WAS ONE
19 OTHER.

20 MS. BONNEVILLE: CAN I ASK ACTUALLY WHAT
21 THE -- I LOST TRACK OF WHAT THE FRIENDLY AMENDMENT
22 TO THE AMENDMENT TO THE ORIGINAL MOTION WAS, THE
23 DIFFERENCE BETWEEN WHAT STEVE HAD PROPOSED AND WHAT
24 DR. YAMAMOTO IS PROPOSING SO WE CAN GET THAT ON
25 RECORD.

BETH C. DRAIN, CA CSR NO. 7152

1 DR. YAMAMOTO: SO WHAT I WAS PROPOSING
2 WOULD BE THAT WE WOULD -- WE MODIFIED THE AMENDMENT,
3 I GUESS, BUT THE PROPOSAL WOULD BE THAT CIRM WOULD
4 INVITE VACCINE DEVELOPMENT PROPOSALS, SPECIFICALLY
5 INVITE VACCINE DEVELOPMENT PROPOSALS FOR COVID-19
6 THAT EMPLOY STEM CELLS, PROGENITOR CELLS, THE
7 TECHNOLOGIES THAT THIS GROUP REALLY FOCUSES ON AND
8 HAS EXPERTISE. AND SO HOPEFULLY IT WILL ATTRACT
9 PEOPLE THAT ARE WORKING IN STEM CELLS TO THINK ABOUT
10 THEIR WORK THROUGH THAT LENS.

11 I MIGHT JUST SAY THAT, MAYBE JUST RELATE
12 TO PEOPLE WHAT THE NIH IS DOING IN THIS REGARD. AND
13 THAT IS THAT ANYBODY HOLDING AN NIH GRANT WHO WANTS
14 TO PIVOT TO DO -- HAS AN IDEA TO DO SOMETHING WITH
15 COVID-19 CAN DO THAT AS LONG AS THAT PIVOT
16 REPRESENTS A SHIFT IN THE FOCUS OF THE ESTABLISHED
17 TECHNOLOGIES AND INTELLECTUAL APPROACHES OF THAT
18 FUNDED GRANT APPLICATION. AND THAT'S HOW THEY
19 DEFINE BEING WITHIN SCOPE. AND SO IF THAT'S DONE,
20 IF YOU HAVE AN IDEA FOR HOW SOME MOLECULAR
21 BIOLOGICAL PROCESS THAT YOU ARE EXPLORING CAN BE
22 USED TO ADVANTAGE TO SHIFT OVER TO FOCUSING ON
23 COVID-19 OR SARS COV2 BIOLOGY, THEN THAT WILL BE
24 REGARDED AS IN SCOPE, AND YOU CAN USE YOUR GRANT
25 MONEY IN THAT WAY. BUT ANYTHING THAT DEPARTS FROM

BETH C. DRAIN, CA CSR NO. 7152

1 THAT FOCUS OF JUST MOVING YOUR TECHNOLOGIES OR
2 APPROACHES FROM WHATEVER THE GRANT WAS FUNDED FOR TO
3 COVID-19 WOULD NOT BE REGARDED AS IN SCOPE.

4 THIS IS EXACTLY WHAT WE'RE TALKING ABOUT
5 HERE. THAT IS TO SAY, CIRM SUPPORTS WORK THAT
6 FOCUSES ON STEM CELLS. IF YOU HAVE AN IDEA OF USING
7 STEM CELLS TO DEVELOP A COVID-19 VACCINE, THAT'S
8 ACTUALLY WITHIN SCOPE AND WE INVITE IT AND ENCOURAGE
9 IT, AND WE'LL BE ABLE TO SUPPORT THAT KIND OF WORK.
10 SO I THINK THIS ALIGNS VERY WELL WITH THE WAY THAT
11 NIH IS THINKING ABOUT THIS.

12 MR. TORRES: AND YOUR AMENDMENT
13 PARLIAMENTARILY REFERRED TO THE ORIGINAL MOTION THAT
14 WAS PROPOSED TO US BY GILBERT, AND THAT IS INCREASE
15 SCOPE OF EARLY STAGE OPPORTUNITIES, DISC AND TRAN,
16 TO INCLUDE VACCINE DEVELOPMENT, AND THAT'S WHERE
17 YOUR AMENDMENT WOULD FIT IN.

18 DR. YAMAMOTO: RIGHT. THANK YOU, SIR.

19 CHAIRMAN THOMAS: MR. HARRISON, I HAVE A
20 QUESTION.

21 MS. BONNEVILLE: WE HAVE TWO MORE
22 COMMENTS, J.T., JUST SO YOU KNOW FROM DAVE MARTIN
23 AND OS STEWARD.

24 CHAIRMAN THOMAS: BEFORE WE GET TO THOSE,
25 JUST A QUESTION. SO THE PROP 71 AS IT IS ALLOWS FOR

BETH C. DRAIN, CA CSR NO. 7152

1 APPLICATIONS THAT ARE STEM CELL RELATED IN THE
2 VACCINE SPACE, AS EVIDENCED BY THE FACT THAT WE'VE
3 ALREADY HAD A COUPLE OF PROPOSALS THAT HAVE COME IN
4 THAT HAVE BEEN VACCINE ORIENTED, SO GIVEN THAT, MR.
5 HARRISON, DO WE NEED THIS AMENDMENT?

6 MR. HARRISON: WELL, YOU NEED THE
7 AMENDMENT TO LIMIT THE SCOPE OF THE PROPOSAL TO
8 VACCINE PROPOSALS THAT HAVE A STEM CELL OR
9 PROGENITOR CELL COMPONENT. I DON'T THINK YOU WOULD
10 NEED TO AMEND THE CONCEPT PLAN BECAUSE, AS IT STANDS
11 NOW, I THINK THOSE PROJECTS WOULD BE ELIGIBLE. IF
12 THE MOTION ON THE TABLE WOULD EXPAND THAT, YOU NEED
13 TO EITHER REMOVE THAT COMPONENT ENTIRELY OR LIMIT IT
14 AS DR. YAMAMOTO PROPOSED.

15 MR. TORRES: AGREED.

16 CHAIRMAN THOMAS: THANK YOU. OKAY.
17 ADDITIONAL COMMENTS, MARIA?

18 MS. BONNEVILLE: OS HAS IS HAND UP. I
19 THINK DAVE PUT HIS DOWN. I THINK IT'S JUST OS.

20 DR. STEWARD: MY QUESTION WAS REALLY THE
21 SAME AS YOURS, MARIA, AND IT WAS SORT OF WHAT IS THE
22 MOTION. JAMES JUST SUMMARIZED IT. LET ME JUST SEE
23 IF I UNDERSTAND IT.

24 SO WE ARE NOT INVITING PROPOSALS IN THE
25 VACCINE DEVELOPMENT DOMAIN EXCEPT FOR THOSE THAT

BETH C. DRAIN, CA CSR NO. 7152

1 FALL WITHIN THE SCOPE OF PROP 71 ANYWAY, BUT WE ARE
2 STRONGLY ENCOURAGING IT. AM I CORRECT IN THAT
3 SUMMARY?

4 MR. HARRISON: THAT'S MY UNDERSTANDING OF
5 THE MOTION.

6 DR. MELMED: POINT OF CLARIFICATION, J.T.
7 WHY DO WE NEED A MOTION THEN BECAUSE IF WE'RE WITHIN
8 THE SCOPE OF CIRM, WHY DO WE NEED A MOTION?

9 CHAIRMAN THOMAS: MY QUESTION WAS ABOUT
10 DR. YAMAMOTO'S AMENDMENT TO THE AMENDMENT. I THINK
11 WE DO NEED THE SENTIMENT TO NOT CONSIDER VACCINE
12 DEVELOPMENT AS A VITAL RESEARCH OPPORTUNITY THAT
13 WOULD NOT CONTEMPLATE A STEM CELL COMPONENT. THE
14 ORIGINAL MOTION WAS, I THINK MR. JUELSGAARD'S MOTION
15 WAS TO REMOVE THAT FROM THE LIST OF THINGS THAT WE
16 ARE CONSIDERING FOR APPROVAL. DR. YAMAMOTO ADDED TO
17 THAT THE FRIENDLY AMENDMENT TO SAY THAT WE ARE
18 ENCOURAGING PROPOSALS THAT WOULD BE STEM CELL
19 RELATED, BUT THAT WAS THE REASON I ASKED
20 MR. HARRISON THE QUESTION. I'M NOT SURE WHY THAT'S
21 NECESSARY EITHER. I THINK THE MOTION TO REMOVE IT
22 AS A VITAL RESEARCH OPPORTUNITY FROM THE ORIGINAL
23 MOTION IS NEEDED, NOT SURE THE LATTER IS BECAUSE
24 IT'S ALREADY CONTEMPLATED BY PROP 71.

25 MR. TORRES: DOESN'T HURT TO REPEAT IT.

BETH C. DRAIN, CA CSR NO. 7152

1 MS. BONNEVILLE: AND DAVE MARTIN STILL HAS
2 A COMMENT. SORRY. HIS HAND IS BACK UP.

3 CHAIRMAN THOMAS: YES, DR. MARTIN.

4 DR. MARTIN: I WOULD LIKE TO SEE, RATHER
5 THAN JUST BEING SILENT ON THE PREDECESSOR SYSTEMS OF
6 STEM CELLS AND PROGENITOR CELLS, A SPECIFIC
7 ENCOURAGEMENT FOR WHAT KEITH HAS SAID IN TERMS OF
8 SOLICITING SUCH PROPOSALS BECAUSE I THINK THERE ARE
9 TWO POSITIVE POTENTIAL BENEFITS OF THAT. THE FIRST
10 IS I THINK I WOULD BELIEVE AND BE VERY SURPRISED IF
11 WE DID NOT SEE A HIGHER QUALITY OF PROPOSALS USING
12 OR DEPLOYING IN SOME WAY STEM CELLS AND/OR
13 PROGENITOR CELLS. THAT'S NO. 1.

14 AND NO. 2, THE SECOND IS I THINK THAT WE
15 WOULD BE POSITIVELY ENCOURAGING THOSE INDIVIDUALS
16 AND INSTITUTIONS WHO ARE HIGHLY EXPERIENCED AND
17 EXPERTS IN STEM CELL AND PROGENITOR CELL
18 APPLICATIONS TO THINK SERIOUSLY ABOUT AND APPLY FOR
19 VACCINE APPLICATIONS. I THINK THOSE ARE TWO VERY
20 SIGNIFICANT POSITIVE GAINS BY BEING VERY SOLICITOUS.

21 DR. YAMAMOTO: YEAH. WE SHOULD BE
22 PROACTIVE. IT'S IMPORTANT.

23 CHAIRMAN THOMAS: ANY OTHER COMMENTS BY
24 MEMBERS OF THE BOARD ON THE AMENDED MOTION?

25 MR. TORRES: CALL FOR THE QUESTION.

BETH C. DRAIN, CA CSR NO. 7152

1 CHAIRMAN THOMAS: ANY COMMENTS BY MEMBERS
2 OF THE PUBLIC ON THIS AMENDED MOTION?

3 MS. BONNEVILLE: I SEE NO HANDS RAISED.

4 CHAIRMAN THOMAS: OKAY. SO HEARING THAT,
5 WE ARE NOW GOING TO VOTE ON THE AMENDMENT PROPOSED
6 BY MR. JUELSGAARD AS MODIFIED BY DR. YAMAMOTO. THIS
7 IS NOT A VOTE ON THE ORIGINAL MOTION. SO, MARIA,
8 WILL YOU PLEASE CALL THE ROLL.

9 MR. TORRES: EXCUSE ME. PARLIAMENTARILY
10 THE AMENDMENT BY THE GOOD DOCTOR FROM UCSF WAS TO
11 THE MAIN LANGUAGE OF THE INITIATIVE PROPOSED BY DR.
12 SAMBRANO. BECAUSE DR. JUELSGAARD SAID HE ACCEPTED
13 IT AS A FRIENDLY AMENDMENT, SO THE AMENDMENT IS TO
14 THE MAIN LANGUAGE.

15 CHAIRMAN THOMAS: MY UNDERSTANDING WAS HE
16 WAS AMENDING MR. JUELSGAARD'S MOTION, BUT NOT THE
17 ORIGINAL MOTION.

18 MR. TORRES: BUT MR. JUELSGAARD'S MOTION
19 WAS TO THE MAIN LANGUAGE, AND HE ACCEPTED IT AS A
20 FRIENDLY AMENDMENT. THEREFORE, THE MOTION IS TO
21 AMEND THE MAIN LANGUAGE.

22 CHAIRMAN THOMAS: YES, I THINK WE ARE
23 SAYING THE SAME THING ACTUALLY.

24 DR. YAMAMOTO: YES. IT MEANS THAT WE ARE
25 VOTING ON THE OVERALL.

BETH C. DRAIN, CA CSR NO. 7152

1 CHAIRMAN THOMAS: SO, MARIA, WILL YOU
2 PLEASE CALL THE ROLL.

3 DR. MELMED: J.T., COULD YOU ARTICULATE
4 WHAT A YES OR A NO VOTE MEANS? I'M NOT FOLLOWING.

5 CHAIRMAN THOMAS: A YES VOTE IS TO REMOVE
6 THE VACCINE DEVELOPMENT IDEA AS PART OF THE ORIGINAL
7 MOTION, WHICH INCLUDES VARIOUS THINGS ABOUT DISC1
8 AND DISC2 AND EVERYTHING ELSE, TO REMOVE THAT
9 PARTICULAR COMPONENT FROM THE ORIGINAL MOTION AND
10 HAVE DR. YAMAMOTO'S LANGUAGE AUGMENTING THAT
11 AMENDMENT AS PART OF WHAT WE ARE VOTING ON. SO WE
12 ARE NOT VOTING ON THE ORIGINAL MOTION. WE ARE
13 VOTING ON REMOVING IT AS A VRO TOPIC AND HAVING THE
14 EMPHASIS PLACED ON STEM CELL-RELATED PROJECTS. IS
15 THAT CORRECT, MR. HARRISON?

16 MR. HARRISON: THAT'S CORRECT.

17 CHAIRMAN THOMAS: THANK YOU. MARIA, WILL
18 YOU PLEASE CALL THE ROLL.

19 MS. BONNEVILLE: J.T., I THINK OS HAS A
20 FINAL QUESTION.

21 CHAIRMAN THOMAS: DR. STEWARD.

22 DR. STEWARD: NO. THAT CLARIFIED IT. I'M
23 SORRY. I WAS STILL A LITTLE CONFUSED. I JUST
24 WANTED TO BE UNCONFUSED.

25 MS. BONNEVILLE: THANK YOU.

BETH C. DRAIN, CA CSR NO. 7152

1 GEORGE BLUMENTHAL.
2 DR. BLUMENTHAL: YES.
3 MS. BONNEVILLE: LINDA BOXER. KEN BURTIS.
4 DR. BURTIS: YES.
5 MS. BONNEVILLE: DEBORAH DEAS. ANNE-MARIE
6 DULIEGE.
7 DR. DULIEGE: YES.
8 MS. BONNEVILLE: YSABEL DURON.
9 MS. DURON: YES.
10 MS. BONNEVILLE: JUDY GASSON. DAVID
11 HIGGINS.
12 DR. HIGGINS: YES.
13 MS. BONNEVILLE: STEPHEN JUELSGAARD.
14 MR. JUELSGAARD: YES.
15 MS. BONNEVILLE: LINDA MALKAS.
16 DR. MALKAS: YES.
17 MS. BONNEVILLE: DAVE MARTIN.
18 DR. MARTIN: YES.
19 MS. BONNEVILLE: SHLOMO MELMED.
20 DR. MELMED: YES.
21 MS. BONNEVILLE: LAUREN MILLER.
22 MS. MILLER: YES.
23 MS. BONNEVILLE: ADRIANA PADILLA. JOE
24 PANETTA.
25 MR. PANETTA: YES.

BETH C. DRAIN, CA CSR NO. 7152

1 MS. BONNEVILLE: FRANCISCO PRIETO.
2 DR. PRIETO: AYE.
3 MS. BONNEVILLE: ROBERT QUINT.
4 DR. QUINT: ABSTAIN.
5 MS. BONNEVILLE: AL ROWLETT.
6 MR. ROWLETT: YES.
7 MS. BONNEVILLE: SUZANNE SANDMEYER. JEFF
8 SHEEHY.
9 MR. SHEEHY: ABSTAIN.
10 MS. BONNEVILLE: OSWALD STEWARD.
11 DR. STEWARD: YES.
12 MS. BONNEVILLE: JONATHAN THOMAS.
13 CHAIRMAN THOMAS: SO I'M PERSUADED. YES.
14 MS. BONNEVILLE: ART TORRES.
15 MR. TORRES: AYE.
16 MS. BONNEVILLE: KRISTINA VUORI.
17 DR. VUORI: YES.
18 MS. BONNEVILLE: DIANE WINOKUR.
19 MS. WINOKUR: YES.
20 MS. BONNEVILLE: KEITH YAMAMOTO.
21 DR. YAMAMOTO: YES.
22 MS. BONNEVILLE: DOUG ZIEDONIS.
23 THE MOTION CARRIES.
24 CHAIRMAN THOMAS: OKAY. THANK YOU. NOW
25 WITH THAT REMOVED FROM THE ORIGINAL MOTION, WE NOW

BETH C. DRAIN, CA CSR NO. 7152

1 HAVE THAT MOTION ON THE TABLE. IS THERE ANY FURTHER
2 DISCUSSION ON THAT MOTION? ANY COMMENTS BY MEMBERS
3 OF THE PUBLIC ON THAT MOTION? HEARING NONE, MARIA,
4 PLEASE CALL THE ROLL.

5 DR. STEWARD: ACTUALLY I DO HAVE A
6 COMMENT. THIS IS OS. SO I'D JUST LIKE TO HEAR A
7 LITTLE BIT MORE ABOUT THE RATIONALE FOR INCREASING
8 THE TOTAL AMOUNT FOR DISC2 TO \$250,000. I'M ASKING
9 THIS IN A WAY SORT OF RELATED TO ALL THE OTHER
10 COMMENTS THAT WERE BROUGHT UP EARLIER.

11 THIS IS A ZERO-SUM GAME. WE HAVE \$5
12 MILLION. AND SO THE NUMBER OF THINGS WE CAN FUND IS
13 LIMITED BY THE TOTAL THAT WE GIVE OUT FOR INDIVIDUAL
14 THINGS. SO I JUST WANT TO UNDERSTAND WHY 250 IS NOW
15 CRITICAL. THANK YOU.

16 CHAIRMAN THOMAS: DR. SAMBRANO.

17 DR. SAMBRANO: SO THE REASON WE RAISED IT
18 TO TWO FIFTY WAS TO ALIGN IT WITH HOW THE PROGRAMS
19 OUTSIDE OF THE COVID-19 PROGRAM EXIST. SO FOR DISC2
20 WE ALLOW THERAPEUTIC DEVELOPMENT WHICH USUALLY HAS A
21 GREATER DOLLAR AMOUNT, RECOGNIZING THAT THERAPEUTICS
22 WILL TYPICALLY TAKE MORE FUNDS TO DEVELOP THAN, SAY,
23 A TOOL OR A DIAGNOSTIC AND SO ON. AND ALSO THE
24 ADDITION OF THE DISC1, WHICH WE ARE PUTTING IN AT A
25 HUNDRED FIFTY K, WE ALSO WANTED TO DISTINGUISH IT

BETH C. DRAIN, CA CSR NO. 7152

1 FROM THAT ONE AND RAISE THE ALLOWABLE AMOUNT FOR IT.

2 I THINK WE ALSO HAVE SEEN IN SOME OF THE
3 DISC2 PROJECTS THAT HAVE COME IN SOME FEASIBILITY
4 ISSUES WITH BEING ABLE TO ACHIEVE A CANDIDATE. SO
5 WE THOUGHT THAT INCREASING THE AMOUNT MAY ALSO
6 INCREASE THE LIKELIHOOD THAT WE GET BETTER PROJECTS.

7 CHAIRMAN THOMAS: OS, DO YOU HAVE A
8 FOLLOW-UP QUESTION?

9 DR. STEWARD: NO FOLLOW-UP QUESTION. I
10 GUESS I'M STILL NOT QUITE CONVINCED. AND, AGAIN,
11 IT'S BECAUSE THERE IS A LOT OF MONEY OUT THERE FROM
12 OTHER SOURCES. AND WE HAVE AN EXCEEDINGLY SMALL
13 AMOUNT OF MONEY TO USE FOR THIS WHOLE COVID
14 INITIATIVE. IT JUST MEANS THAT THINGS ARE GOING TO
15 GET MORE COMPETITIVE IN TERMS OF A NUMBER OF THINGS
16 THAT WE ARE SEEING AND THE AMOUNT THAT WE HAVE
17 AVAILABLE. SO PART OF ME WOULD PREFER TO USE A
18 LITTLE BIT OF MONEY IN THE HOPE THAT WE WOULD SEE
19 SOME REALLY COOL THINGS AND SEE MORE OF THEM RATHER
20 THAN TRYING TO MAKE SURE THAT THE ONES WE DO FUND
21 HAVE ENOUGH. THAT'S MY CONCERN. THANK YOU.

22 CHAIRMAN THOMAS: OTHER COMMENTS FROM
23 MEMBERS OF THE BOARD? IS THERE COMMENTS BY MEMBERS
24 OF THE PUBLIC? OKAY. HEARING NONE, OS, I WASN'T
25 HEARING AN AMENDMENT. SO I'M ASSUMING YOU'RE NOT

BETH C. DRAIN, CA CSR NO. 7152

1 PROPOSING THAT AND WE SHOULD PROCEED TO A VOTE; IS
2 THAT CORRECT?

3 DR. STEWARD: YEAH, THAT'S CORRECT. I'M
4 SORT OF UNENTHUSIASTIC ABOUT THAT AMOUNT, BUT NOT
5 UNENTHUSIASTIC ENOUGH TO VOTE AGAINST IT. I DID
6 WANT TO THROW IT OUT THERE AND SEE IF ANYONE ELSE
7 HAD COMMENTS; BUT IF NO ONE ELSE DOES, THEN I'M
8 FINE. THANK YOU.

9 CHAIRMAN THOMAS: THANK YOU. MARIA, WILL
10 YOU PLEASE CALL THE ROLL.

11 MS. BONNEVILLE: GEORGE BLUMENTHAL.

12 DR. BLUMENTHAL: YES.

13 MS. BONNEVILLE: KEN BURTIS.

14 DR. BURTIS: YES.

15 MS. BONNEVILLE: ANNE-MARIE DULIEGE.

16 DR. DULIEGE: YES.

17 MS. BONNEVILLE: YSABEL DURON.

18 MS. DURON: YES.

19 MS. BONNEVILLE: DAVID HIGGINS.

20 DR. HIGGINS: YES.

21 MS. BONNEVILLE: STEPHEN JUELSGAARD.

22 MR. JUELSGAARD: YES.

23 MS. BONNEVILLE: LINDA MALKAS.

24 DR. MALKAS: YES.

25 MS. BONNEVILLE: DAVE MARTIN.

BETH C. DRAIN, CA CSR NO. 7152

1 DR. MARTIN: YES.
2 MS. BONNEVILLE: SHLOMO MELMED.
3 DR. MELMED: YES.
4 MS. BONNEVILLE: LAUREN MILLER. JOE
5 PANETTA.
6 MR. PANETTA: YES.
7 MS. BONNEVILLE: FRANCISCO PRIETO.
8 DR. PRIETO: AYE.
9 MS. BONNEVILLE: ROBERT QUINT.
10 DR. QUINT: NO.
11 MS. BONNEVILLE: AL ROWLETT.
12 MR. ROWLETT: YES.
13 MS. BONNEVILLE: JEFF SHEEHY.
14 MR. SHEEHY: ABSTAIN.
15 MS. BONNEVILLE: OSWALD STEWARD.
16 DR. STEWARD: YES.
17 MS. BONNEVILLE: JONATHAN THOMAS.
18 CHAIRMAN THOMAS: YES.
19 MS. BONNEVILLE: ART TORRES.
20 MR. TORRES: I THOUGHT I WAS PRECLUDED
21 HERE.
22 MS. BONNEVILLE: NO.
23 MR. TORRES: AYE.
24 MS. BONNEVILLE: KRISTINA VUORI.
25 DR. VUORI: YES.

BETH C. DRAIN, CA CSR NO. 7152

1 MS. BONNEVILLE: DIANE WINOKUR.

2 MS. WINOKUR: NO.

3 MS. BONNEVILLE: KEITH YAMAMOTO.

4 DR. YAMAMOTO: YES.

5 MS. DURON: MARIA, IT'S YSABEL HERE IN
6 CASE I MISSED THE VOTE. YES.

7 MS. BONNEVILLE: GREAT. MOTION CARRIES.

8 CHAIRMAN THOMAS: THANK YOU, MARIA. THERE
9 IS ONE OTHER TOPIC --

10 MS. BONNEVILLE: TWO TOPICS THAT NEED TO
11 BE TAKEN UP, AND IT IS NOON, AFTER NOON. SO I'M
12 HOPING WE HAVE -- WE ARE A COUPLE PEOPLE SHORT
13 POSSIBLY. SO I'M HOPING EVERYONE CAN STAY ON FOR
14 ANOTHER 15, 20 MINUTES IF THAT'S POSSIBLE.

15 CHAIRMAN THOMAS: THERE'S ONE OTHER TOPIC
16 IN DR. SAMBRANO'S PRESENTATION PLUS AN ADDITIONAL
17 MINISTERIAL TOPIC TO TAKE UP. THEN WE'LL BE THROUGH
18 THE AGENDA. SO IF EVERYBODY WILL BEAR WITH US, I
19 WOULD APPRECIATE IT.

20 DR. SAMBRANO, CAN YOU CONTINUE ON THE
21 NOTION OF THE SUPPLEMENTAL AWARDS?

22 DR. SAMBRANO: SURE. IF I COULD HAVE THE
23 NEXT SLIDE PLEASE.

24 VERY QUICKLY, THIS IS A PROPOSAL TO USE UP
25 TO \$1 MILLION FROM THE PROGRAM ALLOCATION FROM THE

BETH C. DRAIN, CA CSR NO. 7152

1 FIVE MILLION THAT WERE ALLOCATED TO ALLOW FOR
2 SUPPLEMENTAL FUNDING OF ACTIVE COVID-19 CLINICAL
3 STAGE AWARDS THAT EXPAND THEIR EFFORTS. AND SO THE
4 SUPPLEMENTAL FUNDING WOULD NOT EXCEED 250,000 IN
5 EACH INSTANCE AND, OF COURSE, WOULD NOT BE USED TO
6 COVER PROJECT COSTS THAT WERE ALREADY COVERED UNDER
7 THE ORIGINAL GRANT AWARD.

8 AND SO IN REQUESTS FOR THIS TYPE OF
9 FUNDING, BECAUSE IT IS ESSENTIALLY THE SAME PROJECT,
10 JUST EITHER, FOR EXAMPLE, INCREASING THE NUMBER OF
11 PATIENTS TO BE TREATED WOULD BE BROUGHT TO THE
12 GOVERNING BOARD'S APPLICATION REVIEW SUBCOMMITTEE
13 FOR APPROVAL AFTER IT HAS BEEN REVIEWED BY CIRM. SO
14 THAT'S IT.

15 CHAIRMAN THOMAS: THANK YOU, DR. SAMBRANO.
16 DO I HEAR A MOTION TO APPROVE THIS ITEM?

17 DR. DULIEGE: I MAKE THE MOTION.

18 CHAIRMAN THOMAS: MOVED BY DR. DULIEGE.

19 MS. DURON: SECOND.

20 CHAIRMAN THOMAS: SECONDED BY MS. DURON.

21 MS. BONNEVILLE: I'M SORRY. YSABEL CANNOT
22 COMMENT ON THE MOTION.

23 CHAIRMAN THOMAS: DO I HEAR A SECOND?

24 MR. ROWLETT: SECOND.

25 CHAIRMAN THOMAS: THANK YOU VERY MUCH,

BETH C. DRAIN, CA CSR NO. 7152

1 MR. ROWLETT.

2 FURTHER DISCUSSION BY MEMBERS OF THE
3 BOARD? NO HANDS UP, MARIA?

4 MS. BONNEVILLE: I DO NOT SEE HANDS.

5 CHAIRMAN THOMAS: OKAY. ANY COMMENTS BY
6 MEMBERS OF THE PUBLIC? HEARING NONE, MARIA, WILL
7 YOU PLEASE CALL THE ROLL.

8 MS. BONNEVILLE: GEORGE BLUMENTHAL.

9 DR. BLUMENTHAL: YES.

10 MS. BONNEVILLE: ANNE-MARIE DULIEGE.

11 DR. DULIEGE: YES.

12 MS. BONNEVILLE: DAVID HIGGINS.

13 DR. HIGGINS: YES.

14 MS. BONNEVILLE: STEPHEN JUELSGAARD.

15 MR. JUELSGAARD: YES.

16 MS. BONNEVILLE: DAVE MARTIN.

17 DR. MARTIN: YES.

18 MS. BONNEVILLE: LAUREN MILLER. JOE
19 PANETTA.

20 MR. PANETTA: YES.

21 MS. BONNEVILLE: FRANCISCO PRIETO.

22 DR. PRIETO: AYE.

23 MS. BONNEVILLE: ROBERT QUINT.

24 DR. QUINT: ABSTAIN.

25 MS. BONNEVILLE: AL ROWLETT.

BETH C. DRAIN, CA CSR NO. 7152

1 MR. ROWLETT: YES.
2 MS. BONNEVILLE: JEFF SHEEHY.
3 MR. SHEEHY: YES.
4 MS. BONNEVILLE: JONATHAN THOMAS.
5 CHAIRMAN THOMAS: YES.
6 MS. BONNEVILLE: KRISTINA VUORI.
7 DR. VUORI: I'M NOT IN CONFLICT? YES.
8 MS. BONNEVILLE: DIANE WINOKUR.
9 MS. WINOKUR: YES.
10 MS. BONNEVILLE: THE MOTION CARRIES.
11 CHAIRMAN THOMAS: THANK YOU, MARIA.
12 LAST ITEM OF THE ACTION ITEMS IS
13 APPOINTMENT AND REAPPOINTMENT OF SCIENTIFIC MEMBERS
14 TO THE GRANTS WORKING GROUP. I THINK YOU'VE SEEN
15 THE MATERIAL HERE. DO I HAVE A MOTION TO APPROVE?
16 DR. PRIETO: SO MOVED.
17 MS. DURON: SECOND.
18 CHAIRMAN THOMAS: ARE THERE ANY COMMENTS
19 BY MEMBERS OF THE BOARD OR QUESTIONS OF DR. SAMBRANO
20 WITH RESPECT TO THIS ITEM? HEARING NONE, ANY
21 COMMENTS BY MEMBERS OF THE PUBLIC ON THIS ITEM?
22 HEARING NONE, MARIA, WILL YOU PLEASE CALL THE ROLL.
23 MS. BONNEVILLE: GEORGE BLUMENTHAL.
24 DR. BLUMENTHAL: YES.
25 MS. BONNEVILLE: LINDA BOXER. KEN BURTIS.

BETH C. DRAIN, CA CSR NO. 7152

1 DR. BURTIS: YES.
2 MS. BONNEVILLE: DEBORAH DEAS. ANNE-MARIE
3 DULIEGE.
4 DR. DULIEGE: YES.
5 MS. BONNEVILLE: YSABEL DURON.
6 MS. DURON: YES.
7 MS. BONNEVILLE: JUDY GASSON. DAVID
8 HIGGINS.
9 DR. HIGGINS: YES.
10 MS. BONNEVILLE: STEPHEN JUELSGAARD.
11 MR. JUELSGAARD: YES.
12 MS. BONNEVILLE: LINDA MALKAS. DAVE
13 MARTIN.
14 DR. MARTIN: YES.
15 MS. BONNEVILLE: SHLOMO MELMED.
16 DR. MELMED: YES.
17 MS. BONNEVILLE: LAUREN MILLER. ADRIANA
18 PADILLA. JOE PANETTA.
19 MR. PANETTA: YES.
20 MS. BONNEVILLE: FRANCISCO PRIETO.
21 DR. PRIETO: AYE.
22 MS. BONNEVILLE: ROBERT QUINT.
23 DR. QUINT: YES.
24 MS. BONNEVILLE: AL ROWLETT.
25 MR. ROWLETT: YES.

BETH C. DRAIN, CA CSR NO. 7152

1 MS. BONNEVILLE: SUZANNE SANDMEYER. JEFF
2 SHEEHY.

3 MR. SHEEHY: YES.

4 MS. BONNEVILLE: OS STEWARD.

5 DR. STEWARD: YES.

6 MS. BONNEVILLE: JONATHAN THOMAS.

7 CHAIRMAN THOMAS: YES.

8 MS. BONNEVILLE: ART TORRES.

9 MR. TORRES: AYE.

10 MS. BONNEVILLE: KRISTINA VUORI.

11 DR. VUORI: YES.

12 MS. BONNEVILLE: DIANE WINOKUR.

13 MS. WINOKUR: YES.

14 MS. BONNEVILLE: KEITH YAMAMOTO. DOUG
15 ZIEDONIS.

16 THE REPORTER: MARIA, WHO WAS THE MAKER OF
17 THAT MOTION?

18 MS. BONNEVILLE: FRANCISCO PRIETO.

19 MOTION CARRIES.

20 CHAIRMAN THOMAS: THANK YOU, BETH, FOR
21 YOUR EXCEPTIONAL WORK.

22 THE REPORTER: THANK YOU.

23 CHAIRMAN THOMAS: WE'RE NOW AT DISCUSSION
24 ITEM, THE TIME OF THE AGENDA FOR MEMBERS OF THE
25 PUBLIC TO COMMENT ON ANY TOPIC OF INTEREST. ARE

BETH C. DRAIN, CA CSR NO. 7152

1 THERE ANY PUBLIC COMMENTS AT THIS TIME? HEARING
2 NONE, THAT CONCLUDES TODAY'S AGENDA. I WANT TO
3 REITERATE DR. HIGGINS AT THE OUTSET GAVE THE MESSAGE
4 I WAS GOING TO GIVE AT THE VERY TAIL END, WHICH WAS
5 TO THANK DOUG AND TRICIA FOR THEIR HARD WORK IN
6 PULLING THIS ALTOGETHER. IN ADDITION TO MARIA,
7 ANOTHER GREAT THANKS TO DR. SAMBRANO FOR HIS WORK
8 AND HIS TEAM'S WORK PULLING TOGETHER THE
9 PRESENTATION FOR TODAY'S MEETING. WITH THAT,
10 EVERYBODY --

11 MR. TORRES: WHOA. WHOA. A FOND FAREWELL
12 TO DR. BURTIS. THIS IS HIS LAST MEETING.

13 MS. BONNEVILLE: NO. THAT MEETING IS IN
14 JUNE.

15 DR. BURTIS: NOT TOO QUICK, ART.

16 CHAIRMAN THOMAS: I KNOW YOU'RE TRYING TO
17 PUSH HIM OUT, ART.

18 MR. TORRES: NO. I'M SURE WE'LL BE
19 WORKING TOGETHER IN MY OTHER CAPACITY.

20 DR. BURTIS: I'LL SEE YOU IN JUNE.

21 CHAIRMAN THOMAS: THANK YOU, EVERYBODY.
22 PLEASE CONTINUE, YOU AND YOUR FAMILIES, TO STAY SAFE
23 AND HEALTHY, AND WE WILL TALK TO YOU NEXT WEEK.

24 MS. BONNEVILLE: I LOVE DR. PRIETO'S MASK.
25 THANKS, EVERYONE.

BETH C. DRAIN, CA CSR NO. 7152

(THE MEETING WAS THEN CONCLUDED AT 12:11 P.M.)

REPORTER'S CERTIFICATE

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE ZOOM PROCEEDINGS BEFORE THE INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS EMERGENCY MEETING HELD ON MAY 15, 2020, WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

BETH C. DRAIN, CA CSR 7152
133 HENNA COURT
SANDPOINT, IDAHO
(208) 255-5453